Revenio: All cylinders are hot
All of Revenio’s market and product areas are performing strongly based on the Q1 report, and we expect strong growth figures also in Q2 and Q3. At the same time, the company is building a long-term growth path with effective investments. In our opinion, the increase in RBT tonometers’ market share, imaging devices, HOME product, and software business provide preconditions for strong growth over the next 10 years.
Login required
This content is only available for logged in users
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures25.04.2021
2020 | 21e | 22e | |
---|---|---|---|
Revenue | 61.1 | 79.3 | 102.5 |
growth-% | 23.41 % | 29.94 % | 29.15 % |
EBIT (adj.) | 19.2 | 27.5 | 35.5 |
EBIT-% (adj.) | 31.44 % | 34.66 % | 34.67 % |
EPS (adj.) | 0.58 | 0.83 | 1.04 |
Dividend | 0.32 | 0.40 | 0.55 |
Dividend % | 0.64 % | 1.41 % | 1.93 % |
P/E (adj.) | 86.56 | 34.22 | 27.38 |
EV/EBITDA | 61.53 | 26.47 | 19.90 |